Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3282818 | Clinical Gastroenterology and Hepatology | 2013 | 9 Pages |
Abstract
USS and SAS are similar in lifetime costs and quality of life, although the current SAS strategy was overall more cost-effective in preventing bone loss and fractures among patients with undiagnosed or subclinical disease. On the basis of best available supportive evidence, it is more cost-effective to maintain the standard celiac screening practices, although future robust population-based evidence in other health outcomes could be leveraged to reevaluate current screening guidelines.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
K.T. Park, Raymond Tsai, Louise Wang, Nasim Khavari, Laura Bachrach, Dorsey Bass,